TickerTalks
Browse all tickers →
TickerTalks›$CRVS
CRCRVS

Corvus Pharmaceuticals, Inc.

$CRVS·$885M·Biotechnology·Healthcare
$9.52-3.4%YTD+26.6%1Y+24.4%
Price updated 6h ago·X counts updated 5d ago
CRCRVS
$CRVSCorvus Pharmaceuticals, Inc.
$9.52-3.35%92 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CRVS on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

92X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $CRVS's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-10

Corvus chatter is small but constructive — a new Immunity paper strengthens the asthma rationale for soquelitinib via the ILC2-serotonin circuit, big volume spike ahead of a possible post-long-weekend deal, and Citadel Advisor's Sept 1 filing shows +70% jump in call value. Cash runway through Q2 2028 keeps solvency off the table.

Read what X is saying about $CRVS

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CRVS — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Corvus pre-trial on soquelitinib for HS plus Citadel's +70% call-value jump — the setup is specific and clinical.

Corvus Pharmaceuticals is a clinical-stage immunotherapy biotech whose lead asset is soquelitinib — an ITK inhibitor with an evolving target-indication list (asthma, hidradenitis suppurativa, oncology). The 2026 catalyst stack is thickening.

  • The P&L is pre-revenue: zero quarterly revenue with EPS of -$0.15 and trailing prints missing Street estimates by 19% and 7% — this is a biotech funded through Q2 2028 cash runway, with the stock trading on data readouts and partnership signals.
  • The specific catalyst stack is unusual: a new Immunity paper strengthening the soquelitinib asthma rationale via the ILC2-serotonin circuit, the newly initiated Phase 1b for hidradenitis suppurativa, big volume spike pre-long-weekend, and Citadel Advisor's Sept 1 filing showing +70% jump in call value.

At 22% of 52-week range and 23% below the 200-day going into Nov 3 earnings, this is a classic small-biotech catalyst coil with institutional positioning. Any specific partnership announcement or Phase 1b data signal is the trigger; a safety signal or dilution surprise is the invalidation.

Agrees with X sentimentThe small-but-constructive bullish framing is grounded on the Immunity paper, the Phase 1b initiation, and the Citadel call-value signal. Cash runway through Q2 2028 is the honest hedge against dilution risk.

What to watch: Nov 3 Q3 earnings and any soquelitinib partnership/data update — cash runway, Phase 1b trial progression, oncology pipeline updates, and any announced strategic partnership. Named partnership is the trigger; safety signal is the invalidation.

On the calendar: 2026-11-03 — Q3 earnings

event ahead 30dclinical catalysts

Read the AI verdict on $CRVS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage immuno-oncology company with lead anti-CD73 antibody mupadolimab in Phase Ib/II trials.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CRVS.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $CRVS

Partial — Clinical-stage immuno-oncology company with lead anti-CD73 antibody mupadolimab in Phase Ib/II trials.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-22.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-19.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-38.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.19$-0.16-19.4%
Q1 2026May 7, 2026$-0.15$-0.14-7.1%
Q4 2025Mar 12, 2026$-0.15$-0.14-7.1%
Q3 2025Nov 4, 2025$-0.12$-0.14+14.3%
Next earningsTue, Nov 3·consensus EPS $-0.19

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.15$-10.5M
Q4 FY25$0———$-0.18$-9.2M
Q3 FY25$0———$-0.12$-9.6M
Q2 FY25$0———$-0.10$-5.9M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.2M$1.2M – $1.2M-$0.75-$0.79 – -$0.675
FY27$3.8M$3.8M – $3.8M-$0.93-$1.12 – -$0.703
FY28$31.8M$31.8M – $31.8M-$0.75-$1.41 – -$0.044
FY29$83.9M$83.9M – $83.9M-$0.33-$0.33 – -$0.332
FY30$159.3M$159.3M – $159.3M$0.13$0.13 – $0.132

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.15%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-25.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-33.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 64.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.865-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJun 11Moore David ScottDirector21.7K sh$250KBuyMay 18Richard A MillerCEO6.9K sh$83K
+ 6 other (6 awards) in window

See when $CRVS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 228-K — Item 5.02: Officer or director change
AI summary

CRVS filed an 8-K under Item 5.02 disclosing a personnel change: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Personnel changes at the executive or board level are typically administrative but can signal strategic shifts depending on context.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Corvus Pharmaceuticals, Inc. held its 2026 Annual Meeting on June 11, 2026, with 73,021,854 of 84,090,424 shares voted. Shareholders elected Class I directors Richard A. Miller M.D. (58.3M for) and Linda S. Grais M.D. J.D. (53.2M for, 7.8M withheld); ratified PricewaterhouseCoopers LLP; and approved Say-on-Pay. Grais drew notable opposition (~13% withheld) — all proposals passed, but the dissent level on one director is worth flagging.

8-KPress release / Reg FDMay 148-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Corvus Pharmaceuticals, Inc. presented final data from its randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis at a medical conference on May 14, 2026. The press release with full data is furnished as Exhibit 99.1. Final Phase 1 data presentation is a clinical catalyst for Corvus — the randomized design and blinded controls provide a higher-quality evidence base than open-label studies, and positive results would support advancing soquelitinib into Phase 2 for atopic dermatitis.

3New insider — initial holdingsApr 273
AI summary

Andrew C. Chan, MD, PhD, filed an initial Form 3 for Corvus Pharmaceuticals (CRVS) on April 23, 2026, reporting his initial beneficial ownership as a newly appointed director. Chan is a prominent immunologist (formerly VP at Genentech). The Form 3 establishes the baseline for his ongoing SEC ownership reporting obligations.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change
AI summary

Corvus Pharmaceuticals (CRVS) appointed Andrew C. Chan, MD, PhD, to its board of directors as a Class II director effective April 23, 2026, serving until the 2027 annual meeting. Chan is a distinguished immunologist who previously led immuno-oncology research at Genentech. His appointment strengthens the company's scientific advisory credentials as it advances cancer immunotherapy programs.

+ 12 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?defenseworld.net·16d agoCorvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativaglobenewswire.com·16d agoCorvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conferenceglobenewswire.com·44d agoCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trialglobenewswire.com·51d agoCorvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcriptseekingalpha.com·71d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport